FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994691784> ?p ?o ?g. }

• W1994691784 endingPage "313" @default.
• W1994691784 startingPage "307" @default.
• W1994691784 abstract "To determine whether a difference in HbA(1c) could be safely sustained between a standard therapy (STD) arm and an intensive therapy (INT) arm, while maintaining HbA(1c) levels in both arms within a range acceptable in community practice. The effects of intensive treatment on various parameters were studied in this feasibility trial. We report here the results of 24 months of INT on peripheral and autonomic neuropathy.A prospective trial was conducted in five medical centers in 153 men of 60 +/- 6 years of age who had a known diagnosis of diabetes for 7.8 +/- 4 years. They were randomly assigned to a standard insulin treatment group (one morning injection per day) or to an intensive therapy group designed to attain near-normal glycemia and a clinically significant separation of glycohemoglobin from the standard arm. A four-step plan was used in the intensive therapy group along with daily self-monitoring of glucose: (1) an evening insulin injection, (2) the same injection adding daytime glipizide, (3) two injections of insulin alone, and (4) multiple daily injections. Peripheral neuropathy was diagnosed clinically by a history and physical examination, and by abnormal autonomic neuropathy Valsalva ratio (VR < 1.2) and RR variation (RRV < 10). An average HbA(1c) separation of 2.07% was achieved with INT, having HbA(1c) at or below 7.3% (p = 0. 001 versus STD). Baseline prevalence of peripheral neuropathy was 53% in STD, and 48% in INT. By 24 months, the prevalence increased to 69% in STD (p = 0.005 versus baseline), and to 64% in INT (p = 0. 008 versus baseline, but no different than STD). Though INT did not reverse all elements of peripheral neuropathy, there was a decreased prevalence of cranial neuropathy (p = 0.053 versus STD) and more frequent preservation of touch sensation in the upper extremities (p = 0.03 versus STD) in INT. At baseline, an abnormal Valsalva ratio and/or RR variation was seen in 38% of STD and 31% of INT. By 24 months in STD, the prevalence rose to 55% (p = 0.0067 versus baseline), and in INT, to 48% (p = 0.012 versus baseline and no different from STD). The prevalence of erectile dysfunction increased from 53% at baseline to 73% at 2 years, p = 0.002 in STD, and from 51% to 73% at 2 years (p = 0.003 versus baseline) and no different from STD. There was no change in the frequency of abnormal gastrointestinal or sweating symptoms. Our conclusion was that 2 years of meticulous glycemic control did not decrease overall prevalence of peripheral or autonomic neuropathy. In fact, the prevalence rose equivalently and significantly in both treatment arms. There was some benefit, however, in decreased frequency of cranial neuropathy and better preservation of touch sensation in INT." @default.
• W1994691784 created "2016-06-24" @default.
• W1994691784 creator A5008547887 @default.
• W1994691784 creator A5011336976 @default.
• W1994691784 creator A5011475259 @default.
• W1994691784 creator A5016218720 @default.
• W1994691784 creator A5035811191 @default.
• W1994691784 creator A5036645546 @default.
• W1994691784 creator A5044974386 @default.
• W1994691784 creator A5046417562 @default.
• W1994691784 creator A5057283626 @default.
• W1994691784 creator A5059944259 @default.
• W1994691784 creator A5085999084 @default.
• W1994691784 date "1999-09-01" @default.
• W1994691784 modified "2023-09-27" @default.
• W1994691784 title "The Effects of Intensive Glycemic Control on Neuropathy in the VA Cooperative Study on Type II Diabetes Mellitus (VA CSDM)" @default.
• W1994691784 cites W1973867380 @default.
• W1994691784 cites W2013645515 @default.
• W1994691784 cites W2070875172 @default.
• W1994691784 cites W2078089300 @default.
• W1994691784 cites W2090237305 @default.
• W1994691784 cites W2091034695 @default.
• W1994691784 cites W2313488710 @default.
• W1994691784 cites W2322256252 @default.
• W1994691784 cites W2337454357 @default.
• W1994691784 cites W4245107010 @default.
• W1994691784 cites W4254000113 @default.
• W1994691784 doi "https://doi.org/10.1016/s1056-8727(99)00062-8" @default.
• W1994691784 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10765007" @default.
• W1994691784 hasPublicationYear "1999" @default.
• W1994691784 type Work @default.
• W1994691784 sameAs 1994691784 @default.
• W1994691784 citedByCount "112" @default.
• W1994691784 countsByYear W19946917842012 @default.
• W1994691784 countsByYear W19946917842013 @default.
• W1994691784 countsByYear W19946917842014 @default.
• W1994691784 countsByYear W19946917842015 @default.
• W1994691784 countsByYear W19946917842016 @default.
• W1994691784 countsByYear W19946917842017 @default.
• W1994691784 countsByYear W19946917842018 @default.
• W1994691784 countsByYear W19946917842019 @default.
• W1994691784 countsByYear W19946917842020 @default.
• W1994691784 countsByYear W19946917842021 @default.
• W1994691784 countsByYear W19946917842022 @default.
• W1994691784 countsByYear W19946917842023 @default.
• W1994691784 crossrefType "journal-article" @default.
• W1994691784 hasAuthorship W1994691784A5008547887 @default.
• W1994691784 hasAuthorship W1994691784A5011336976 @default.
• W1994691784 hasAuthorship W1994691784A5011475259 @default.
• W1994691784 hasAuthorship W1994691784A5016218720 @default.
• W1994691784 hasAuthorship W1994691784A5035811191 @default.
• W1994691784 hasAuthorship W1994691784A5036645546 @default.
• W1994691784 hasAuthorship W1994691784A5044974386 @default.
• W1994691784 hasAuthorship W1994691784A5046417562 @default.
• W1994691784 hasAuthorship W1994691784A5057283626 @default.
• W1994691784 hasAuthorship W1994691784A5059944259 @default.
• W1994691784 hasAuthorship W1994691784A5085999084 @default.
• W1994691784 hasConcept C121332964 @default.
• W1994691784 hasConcept C126322002 @default.
• W1994691784 hasConcept C1276947 @default.
• W1994691784 hasConcept C134018914 @default.
• W1994691784 hasConcept C141071460 @default.
• W1994691784 hasConcept C19720800 @default.
• W1994691784 hasConcept C2776476923 @default.
• W1994691784 hasConcept C2777180221 @default.
• W1994691784 hasConcept C2779306644 @default.
• W1994691784 hasConcept C2779901536 @default.
• W1994691784 hasConcept C2780473172 @default.
• W1994691784 hasConcept C2780668416 @default.
• W1994691784 hasConcept C555293320 @default.
• W1994691784 hasConcept C71924100 @default.
• W1994691784 hasConceptScore W1994691784C121332964 @default.
• W1994691784 hasConceptScore W1994691784C126322002 @default.
• W1994691784 hasConceptScore W1994691784C1276947 @default.
• W1994691784 hasConceptScore W1994691784C134018914 @default.
• W1994691784 hasConceptScore W1994691784C141071460 @default.
• W1994691784 hasConceptScore W1994691784C19720800 @default.
• W1994691784 hasConceptScore W1994691784C2776476923 @default.
• W1994691784 hasConceptScore W1994691784C2777180221 @default.
• W1994691784 hasConceptScore W1994691784C2779306644 @default.
• W1994691784 hasConceptScore W1994691784C2779901536 @default.
• W1994691784 hasConceptScore W1994691784C2780473172 @default.
• W1994691784 hasConceptScore W1994691784C2780668416 @default.
• W1994691784 hasConceptScore W1994691784C555293320 @default.
• W1994691784 hasConceptScore W1994691784C71924100 @default.
• W1994691784 hasIssue "5-6" @default.
• W1994691784 hasLocation W19946917841 @default.
• W1994691784 hasLocation W19946917842 @default.
• W1994691784 hasOpenAccess W1994691784 @default.
• W1994691784 hasPrimaryLocation W19946917841 @default.
• W1994691784 hasRelatedWork W1975302648 @default.
• W1994691784 hasRelatedWork W2017030704 @default.
• W1994691784 hasRelatedWork W205177170 @default.
• W1994691784 hasRelatedWork W2086666326 @default.
• W1994691784 hasRelatedWork W2087222447 @default.
• W1994691784 hasRelatedWork W2106363456 @default.
• W1994691784 hasRelatedWork W2362373360 @default.
• W1994691784 hasRelatedWork W2760509590 @default.

• next